FlyBase Allele Report: Hsap\APP[Aβ42.UAS.Tag:SS(rPENK)]

General Information

Symbol

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}

Species

H. sapiens

Name

FlyBase ID

FBal0324739

Feature type

allele

Associated gene

Hsap\APP

Associated Insertion(s)

Carried in Construct

P{UAS-Aβ42.F}

Also Known As

UAS-Aβ42, UAS-Aβ₄₂, Aβ42, UAS-Aβ^H32.12, UAS-Aβ, UAS-Aβ_1-42

Key Links

Transgenic product class

Mutagen

in vitro construct

Nature of the Allele

Transgenic product class

Mutagen

in vitro construct

(Iijima et al., 2008, Finelli et al., 2004, Iijima et al., 2004)

Progenitor genotype

Carried in construct

P{UAS-Aβ42.F}

Cytology

Description

UASt regulatory sequences drive expression of the Hsap\APP Aβ42 peptide, tagged at the N-terminal end with the Tag:SS(rPENK) signal sequence.

(Finelli et al., 2004)

Construct: Scer\UAS regulatory sequences drive expression of the "Aβ42" peptide (a cleavage product of Hsap\APP) fused to the T:Rnor\PENK (signal peptide) at the N-terminus.

(Iijima et al., 2004)

Allele components

Component

Use(s)

Regulatory region(s)

UASt

binary expression system - regulatory region

Encoded product / tool

Hsap\APP

Tagged with

Tag:SS(rPENK)

signal sequence

Mutations Mapped to the Genome

Curation Data

Type

Location

Additional Notes

References

Variant Molecular Consequences

Associated Sequence Data

DDBJ / EMBL / GenBank

DNA sequence

Protein sequence

UniProtKB/Swiss-Prot

UniProtKB/TrEMBL

Expression Data

Reporter Expression

Additional Information

Statement

Reference

Marker for

Reflects expression of

Reporter construct used in assay

Human Disease Associations

Disease Ontology (DO) Annotations

Models Based on Experimental Evidence ( 1 )

Disease

Evidence

References

model of Alzheimer's disease

CEA

(Sekiya et al., 2018, Belfiori-Carrasco et al., 2017, Gerstner et al., 2017, Singh et al., 2017, Lee et al., 2016, Ling et al., 2014, Singh et al., 2014, Lang et al., 2013, Singh et al., 2013, Lang et al., 2012, Wang et al., 2012, Ling and Salvaterra, 2011, Ling et al., 2009, Iijima et al., 2008, Iijima et al., 2004)

model of Alzheimer's disease 1

CEC

(Deolankar et al., 2023, Hsieh and Chiang, 2023, Liu et al., 2023, Miyazaki et al., 2019, Lee et al., 2012)

CEA

(Cheng et al., 2022, Ring et al., 2022, Shao et al., 2022, Wang et al., 2021, Kikuchi et al., 2020, Hahm et al., 2018, Chiang et al., 2010)

model of tauopathy

CEA

(Chiang et al., 2009)

model of neurodegenerative disease

CEA

(Ng et al., 2013)

model of Parkinson's disease

CEA

(Iijima-Ando et al., 2009)

Modifiers Based on Experimental Evidence ( 1 )

Disease

Interaction

References

model of Alzheimer's disease 1

is ameliorated by Droj2^MI08491

(Ring et al., 2022)

is exacerbated by faf^EP381

(Lee et al., 2012)

is ameliorated by faf^RNAi.UAS.cUa

(Lee et al., 2012)

is ameliorated by par-1^RNAi.UAS.cZa

(Lee et al., 2012)

is ameliorated by slmb^RNAi.UAS.cUa

(Lee et al., 2012)

is exacerbated by Rac1^HMS01258

(Kikuchi et al., 2020)

is exacerbated by Rac1^JF02813

(Kikuchi et al., 2020)

is exacerbated by Hsap\PTEN^C124S.UAS

(Chiang et al., 2010)

is ameliorated by Pi3K21B^GD9810

(Chiang et al., 2010)

is ameliorated by Pten^UAS.cGb

(Chiang et al., 2010)

is exacerbated by Vha68-1¹

(Wang et al., 2021)

is exacerbated by Vha68-1^GD16938

(Wang et al., 2021)

is exacerbated by Vha68-1^HMS02581

(Wang et al., 2021)

is exacerbated by Vha68-1^HMS02962

(Wang et al., 2021)

is ameliorated by nAChRα7^PΔEY6

(Hahm et al., 2018)

is exacerbated by Cortactin^HMS00658

(Cheng et al., 2022)

is ameliorated by Cortactin^UAS.cSa

(Cheng et al., 2022)

is ameliorated by HDAC6^{H237A.H664A.UAS}

(Cheng et al., 2022)

is exacerbated by HDAC6^H237A.UAS

(Cheng et al., 2022)

is ameliorated by HDAC6^UAS.cDa

(Cheng et al., 2022)

is ameliorated by tau^HMS02042

(Cheng et al., 2022)

model of Alzheimer's disease

is ameliorated by CG17249^A362

(Belfiori-Carrasco et al., 2017)

is ameliorated by Hpd^KK105686

(Belfiori-Carrasco et al., 2017)

is ameliorated by Hpd^MI12465

(Belfiori-Carrasco et al., 2017)

is ameliorated by Atg1^Δ3D

(Ling et al., 2009)

is ameliorated by Atg5^RNAi.UAS

(Ling et al., 2009)

is exacerbated by sra^EY07182

(Lee et al., 2016)

is ameliorated by Ctr1B^NIG.7459R

(Lang et al., 2013)

is ameliorated by ATP7^EY07895

(Lang et al., 2013)

is ameliorated by Ctr1C^RNAi.UAS.cLa

(Lang et al., 2013)

is ameliorated by Zip42C.1^RNAi.UAS

(Lang et al., 2012)

is exacerbated by Zip42C.1^UAS.cLa

(Lang et al., 2012)

is ameliorated by Zip42C.1^GD1830

(Lang et al., 2012)

is ameliorated by fabp^hs.PG

(Gerstner et al., 2017)

is ameliorated by Mmus\Fabp7^hs.PG

(Gerstner et al., 2017)

is exacerbated by Hsap\TREM2^{13xlexAop.Tag:MYC,Tag:FLAG}

(Sekiya et al., 2018)

is exacerbated by Hsap\TREM2^{R47H.13xlexAop.Tag:MYC,Tag:FLAG}

(Sekiya et al., 2018)

is ameliorated by Tspo^EY00814

(Lin et al., 2014)

is ameliorated by Tspo^VDRC.cUa

(Lin et al., 2014)

is NOT ameliorated by fz2^UAS.GFP

(Lüchtenborg and Katanaev, 2014)

is NOT ameliorated by sgg^GD1331

(Lüchtenborg and Katanaev, 2014)

is NOT ameliorated by Gαo^GTP.UAS

(Lüchtenborg and Katanaev, 2014)

is exacerbated by Hsap\MAPT^UAS.cWa

(Fulga et al., 2007)

is ameliorated by Hsap\MME^UAS.cIa

(Iijima-Ando et al., 2008)

exacerbates Alzheimer's disease

modeled by Hsap\MAPT^UAS.cWa

(Ando et al., 2016)

model of Parkinson's disease

is ameliorated by dnc¹

(Iijima-Ando et al., 2009)

is exacerbated by rut¹

(Iijima-Ando et al., 2009)

is exacerbated by Miro^Sd32

(Iijima-Ando et al., 2009)

is exacerbated by milt^GD8116

(Iijima-Ando et al., 2009)

is exacerbated by Pka-C1^GD1276

(Iijima-Ando et al., 2009)

is ameliorated by Pka-R2^GD15709

(Iijima-Ando et al., 2009)

Comments on Models/Modifiers Based on Experimental Evidence ( 1 )

Flybase curator comment: Alzheimer disease subtype Alzheimer disease 1 is associated with gene APP.

(Miyazaki et al., 2019)

Disease-implicated variant(s)

Phenotypic Data

Phenotypic Class

abnormal grooming behavior, with Scer\GAL4^elav-C155

(Finelli et al., 2004)

abnormal learning, with Scer\GAL4^elav.PU

(Ping et al., 2015)

abnormal learning, with Scer\GAL4^elav-C155

(Iijima et al., 2004)

abnormal locomotor behavior, with Scer\GAL4^ChAT.7.4

(Iijima-Ando et al., 2009)

abnormal locomotor behavior, with Scer\GAL4^elav-C155

(Singh et al., 2014, Ng et al., 2013, Iijima-Ando et al., 2009, Iijima et al., 2008, Finelli et al., 2004, Iijima et al., 2004)

abnormal locomotor behavior | adult stage, with Scer\GAL4^elav.PLu

(Lang et al., 2012)

abnormal locomotor behavior | adult stage, with Scer\GAL4^elav.PU

(Lee et al., 2016, Ping et al., 2015, Lang et al., 2013)

abnormal locomotor behavior | adult stage | progressive, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

abnormal locomotor behavior | adult stage | progressive, with Scer\GAL4^elav-C155

(Sekiya and Iijima, 2021, Wang et al., 2021, Belfiori-Carrasco et al., 2017, Singh et al., 2017)

abnormal memory, with Scer\GAL4^elav-C155

(Iijima et al., 2008)

abnormal memory | adult stage, with Scer\GAL4^elav.PLu

(Lang et al., 2012)

abnormal memory | adult stage, with Scer\GAL4^elav.PU

(Lang et al., 2013)

abnormal memory | adult stage | progressive, with Scer\GAL4^elav.PU

(Wang et al., 2012)

abnormal neuroanatomy, with Scer\GAL4^elav.PU

(Ping et al., 2015, Lin et al., 2014)

abnormal neuroanatomy, with Scer\GAL4^elav-C155

(Iijima et al., 2004)

abnormal neuroanatomy, with Scer\GAL4^ey-OK107

(Iijima et al., 2004)

abnormal neuroanatomy, with Scer\GAL4^Tab2-201Y

(Ping et al., 2015)

abnormal neuroanatomy | adult stage, with Scer\GAL4^elav.PLu

(Lang et al., 2012)

abnormal neuroanatomy | adult stage, with Scer\GAL4^elav-C155

(Wang et al., 2021, Belfiori-Carrasco et al., 2017, Iijima-Ando et al., 2008)

abnormal neuroanatomy | adult stage | progressive, with Scer\GAL4^elav-C155

(Sekiya et al., 2018)

abnormal neuroanatomy | progressive, with Scer\GAL4^elav.PU

(Lang et al., 2013)

abnormal neuroanatomy | progressive, with Scer\GAL4^Gad1.PU

(Ling and Salvaterra, 2011)

abnormal neuroanatomy | third instar larval stage, with Scer\GAL4^elav.PU

(Lee et al., 2016)

abnormal neurophysiology, with Scer\GAL4^arm.PS

(Chiang et al., 2009)

abnormal neurophysiology, with Scer\GAL4^C57

(Chiang et al., 2009)

abnormal neurophysiology, with Scer\GAL4^elav.PU

(Hahm et al., 2018, Ping et al., 2015)

abnormal neurophysiology, with Scer\GAL4^elav-C155

(Chiang et al., 2009)

abnormal neurophysiology, with Scer\GAL4^G7

(Chiang et al., 2009)

abnormal neurophysiology | adult stage, with Scer\GAL4^elav.PU

(Hahm et al., 2018)

abnormal oxidative stress response | adult stage, with Scer\GAL4^elav.PU

(Lee et al., 2016)

abnormal size | adult stage, with Scer\GAL4^elav-C155

(Belfiori-Carrasco et al., 2017)

abnormal sleep | adult stage, with Scer\GAL4^elav-C155

(Gerstner et al., 2017)

abnormal sleep | adult stage | progressive | RU486 conditional, with Scer\GAL4^{elav.Switch.PO}

(Gerstner et al., 2017)

decreased cell number | progressive, with Scer\GAL4^Gad1.PU

(Ling and Salvaterra, 2011)

decreased efficacy of learning | adult stage, with Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023)

increased cell death, with Scer\GAL4^elav.PU

(Lin et al., 2014)

increased cell death | third instar larval stage, with Scer\GAL4^elav.PU

(Lee et al., 2016)

increased cell size | adult stage, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

partially lethal - majority live, with Scer\GAL4^elav.PU

(Lee et al., 2016)

short lived, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

short lived, with Scer\GAL4^elav.PLu

(Lang et al., 2012)

short lived, with Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023, Lee et al., 2016, Ping et al., 2015, Lin et al., 2014, Lüchtenborg and Katanaev, 2014, Lang et al., 2013)

short lived, with Scer\GAL4^elav-C155

(Sekiya and Iijima, 2021, Singh et al., 2017, Singh et al., 2014, Ng et al., 2013, Iijima-Ando et al., 2008, Iijima et al., 2008, Finelli et al., 2004, Iijima et al., 2004)

short lived, with Scer\GAL4^Toll-6-D42

(Lüchtenborg and Katanaev, 2014)

short lived, with Scer\GAL4^Toll-6-D42, Scer\GAL4^VGlut-OK371

(Lüchtenborg and Katanaev, 2014)

short lived | RU486 conditional, with Scer\GAL4^{elav.Switch.PO}

(Ling and Salvaterra, 2011)

visible, with Scer\GAL4^ey.PH

(Singh et al., 2014)

visible, with Scer\GAL4^GMR.PF

(Ando et al., 2016, Marcora et al., 2014, Singh et al., 2013)

visible, with Scer\GAL4^GMR.PU

(Lüchtenborg and Katanaev, 2014)

visible | adult stage, with Scer\GAL4^GMR.PF

(Singh et al., 2017)

Phenotype Manifest In

adult antennal lobe projection neuron, with Scer\GAL4^elav.PU

(Hahm et al., 2018)

adult brain, with Scer\GAL4^elav.PLu

(Lang et al., 2012)

adult brain, with Scer\GAL4^elav.PU

(Lang et al., 2013)

adult brain, with Scer\GAL4^elav-C155

(Sekiya and Iijima, 2021, Wang et al., 2021, Belfiori-Carrasco et al., 2017, Iijima et al., 2004)

adult brain | progressive, with Scer\GAL4^elav-C155

(Sekiya et al., 2018)

adult brain | progressive, with Scer\GAL4^Gad1.PU

(Ling and Salvaterra, 2011)

autophagosome | adult stage, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

calyx of adult mushroom body, with Scer\GAL4^ey-OK107

(Iijima et al., 2008)

embryonic/larval brain | third instar larval stage, with Scer\GAL4^elav.PU

(Lee et al., 2016)

embryonic/larval glial cell | increased number | third instar larval stage, with Scer\GAL4^elav.PU

(Lee et al., 2016)

eye, with Scer\GAL4^ey.PH

(Singh et al., 2014)

eye, with Scer\GAL4^GMR.PF

(Singh et al., 2017, Ando et al., 2016, Marcora et al., 2014, Singh et al., 2013, Fulga et al., 2007)

eye, with Scer\GAL4^GMR.PU

(Lüchtenborg and Katanaev, 2014)

interommatidial bristle, with Scer\GAL4^ey.PH

(Singh et al., 2014)

interommatidial bristle, with Scer\GAL4^GMR.PF

(Singh et al., 2017)

Kenyon cell, with Scer\GAL4^elav.PU

(Ping et al., 2015)

Kenyon cell, with Scer\GAL4^elav-C155

(Iijima et al., 2004)

Kenyon cell, with Scer\GAL4^Tab2-201Y

(Ping et al., 2015)

neuron

(Hahm et al., 2018)

neuron, with Scer\GAL4^ChAT.7.4

(Iijima-Ando et al., 2009)

neuron, with Scer\GAL4^elav.PU

(Hahm et al., 2018, Ping et al., 2015)

neuron, with Scer\GAL4^elav-C155

(Iijima-Ando et al., 2009, Iijima et al., 2008)

neuron | adult stage, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

neuron | progressive, with Scer\GAL4^Gad1.PU

(Ling and Salvaterra, 2011)

neuropil, with Scer\GAL4^elav-C155

(Iijima et al., 2008)

neuropil, with Scer\GAL4^ey-OK107

(Iijima et al., 2008)

neuropil | adult stage, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

neuropil | adult stage, with Scer\GAL4^elav-C155

(Iijima-Ando et al., 2008)

nuclear membrane | adult stage, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

ommatidium, with Scer\GAL4^ey.PH

(Singh et al., 2014)

ommatidium, with Scer\GAL4^GMR.PF

(Singh et al., 2017)

organelle membrane | adult stage, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

plasma membrane | adult stage, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

vacuole | adult stage | increased number, with Scer\GAL4^elav-C155

(Sekiya and Iijima, 2021)

vesicle | adult stage, with Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

Detailed Description

Statement

Reference

Adults expressing Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)} under the control of Scer\GAL4^elav-C155 show brain vacuolization and a progressive decrease in adult climbing activity.

(Wang et al., 2021)

Expression of Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)} under the control of Scer\GAL4^elav.PU significantly increases spontaneous excitatory post-synaptic current (sEPSC) frequency in the antennal lobe projection neurons of young flies (0-2 days after eclosion) and significantly reduces it in older flies (9-13 days after eclosion), compared to age-matched controls.

Expression of Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)} under the control of Scer\GAL4^elav.PU also causes significant increases in sEPSC frequency and amplitude, with no differences in waveform, in primary cultures of neurons, isolated at the embryonic stage, after 5 days in vitro, compared to controls; after 9 days in vitro, sEPSC frequency and amplitude are significantly decreased, with significantly faster decay times and shorter half-width times of waveforms, compared to controls. Miniature EPSC (mESPC) frequency, but not amplitude, is significantly higher at 5 days in vitro and significantly lower at 9 days in vitro, with no difference in most kinetic measurements, compared to controls, but the relative contribution of the slow component is significantly increased and that of the fast component is significantly decreased at 9 days in vitro.

(Hahm et al., 2018)

Expressing Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)} under the control of Scer\GAL4^elav-C155 leads to neurodegeneration, as evident by present of adult brain vacuolization, as compared to controls.

(Sekiya et al., 2018)

The expression of Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)} under the control of Scer\GAL4^elav-C155 leads to a significant decrease in adult locomotor capacity (in negative geotaxis assays) 18 days post eclosion, but not before that, as compared to controls; this expression also leads to the the adult brain showing a significant area loss and some vacuolization, as compared to controls.

(Belfiori-Carrasco et al., 2017)

Short-term expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} driven by Scer\GAL4^{elav.Switch.PO} (and using RU486 food supplementation to control the time of expression) leads to progressive daytime sleep defects (decrease in overall amount of daytime sleep, average as well as maximum bout length but a slight increase in the number of day sleep bouts, while the sleep consolidation index is concomitantly reduced) and nighttime activity is decreased. However, unrestrained Scer\GAL4^elav-C155-driven expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} induces both daytime and nighttime sleep loss already in 2-3 days old adult males and is accompanied by decreased maximum bout length (both day and night) and the daytime bout number is also significantly reduced.

(Gerstner et al., 2017)

Adult flies expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} under the control of Scer\GAL4^GMR.PF display eye morphology defects of varying severity (including size reduction, ommatidial disruption and bristle loss). Expression under the Scer\GAL4^elav-C155 driver leads to age-progressive decrease of locomotor (climbing) ability and shorter lifespan.

(Singh et al., 2017)

Adults expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} under the control of Scer\GAL4^GMR.PF have eye sizes comparable to controls, but with a rough eye phenotype.

(Ando et al., 2016)

Expression of Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^elav.PU results in significantly decreased survival rate during development as well as shorter adult life-span of the survivors, it also leads to significantly impaired climbing abilities of the adults compared to controls.

Expression of Hsap\APP^{Aβ42.Scer\UAS} results in increased levels of cell death and increased number of glial cells in third instar larval brain when expressed under the control of Scer\GAL4^elav.PU. It also reduces adult survival rate under oxidative stress conditions compared to controls.

(Lee et al., 2016)

Primary neurons that have been dissociated from late-gastrula stage embryos expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} under the control of Scer\GAL4^elav.PU show increased neuronal excitability in 9 day old cultures compared to controls.

Mushroom body neuron cultures expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} under the control of Scer\GAL4^elav.PU show an increase in the delayed rectifier component at one day, although this is lost after the first day. There is a decease in A-type K[+] current density after 9 days of culture compared with controls and this can be reversed when the neurons are cultured in the presence of the proteosome inhibit MG132. Blocking lysosome function by adding leupeptin to the culture blocks the decrease in A-type currents in a concentration-dependent manner.

Adult flies expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} under the control of Scer\GAL4^elav.PU do not exhibit any difference in K[+] current density at 3 days, but by 8 days A-type K[+] current density is significantly reduced in mushroom body neurons. Cell capacitance, resting membrane potential and input resistance are unaffected. Blocking proteosome function in adult flies (by co-expressing Prosβ6^1.B.Scer\UAS and Prosβ2^1.Scer\UAS and shifting to the permissive temperature at eclosion) prevents the reduction in A-type K[+] current density compared with controls.

Larvae expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} pan-neuronally under the control of Scer\GAL4^elav.PU exhibit learning defects in odor-association learning assays. Naive preference for fructose and odors and chemotaxis towards known attractants are similar to controls.

Flies expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} under the control of Scer\GAL4^elav.PU exhibit progressive climbing defects and decreased lifespan compared to controls.

Expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} specifically in the mushroom body under the control of Scer\GAL4^Tab2-201Y results in loss of mushroom body neurons.

(Ping et al., 2015)

Scer\GAL4^elav.PU-mediated expression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa} induces brain neurodegeneration, increases caspase activation, and shortens lifespan.

(Lin et al., 2014)

Pan-neuronal expression of Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^elav.PU reduces lifespan. Flies expressing Hsap\APP^{Aβ42.Scer\UAS} in the motoneurons under the control of Scer\GAL4^D42 show a similar reduction in lifespan, and this phenotype is made more severe by the addition of an additional motoneuron driver, Scer\GAL4^VGlut-OK371.

Expression of Hsap\APP^{Aβ42.Scer\UAS} under the control of either Scer\GAL4^elav.PU, Scer\GAL4^D42 or Scer\GAL4^D42 and Scer\GAL4^VGlut-OK371 has no effect on NMJ morphology or bouton number.

Expression of Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^GMR.PU results in a rough eye phenotype.

(Lüchtenborg and Katanaev, 2014)

Flies expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} under the control of Scer\GAL4^GMR.PF show a rough eye phenotype with areas of necrosis.

(Marcora et al., 2014)

Expression of Hsap\APP^{Aβ42.Scer\UAS} in the compound eye using Scer\GAL4^ey.PH causes severe degeneration in eye tissues ranging from loss of bristles, ommatidial holes to severe ommatidial disruption.

When Hsap\APP^{Aβ42.Scer\UAS}-expressing larvae are grown in medium containing 2-(4' -benzyloxy-phenyl)-3- hydroxy-chromen-4-one, an approximately 70% rescue of the rough eye phenotype is observed. There is also a significant reduction in amyloid plaques in eye imaginal discs of the treated flies compared with controls. The compound also ameliorated the locomotor-deficit resulting from the expression of Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^elav-C155, and also improves the lifespan of these flies.

(Singh et al., 2014)

Adults expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU show a defect in climbing ability starting at 15 days of age, and have a reduced lifespan compared to controls.

30 day old adults expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU show neurodegeneration in both the cortex and neuropil regions of the adult brain.

10 day old adults expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU show impaired memory performance compared to controls in an olfactory aversive conditioning assay.

(Lang et al., 2013)

Expression of Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^elav-C155 results in a reduction of median and maximum lifespan by 17 days and 32 days respectively, when compared to controls. Treatment with an aqueous extract from the rhizome of Gastrodia elata (GE) (1-5mg/g) improves survival. Addition of 1mg/g GE extract increases median and maximum lifespan by 4 days. A 5mg/g GE extract increases the median and maximum lifespan by 7 days.

Expression of Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^elav-C155 significantly impairs locomotion from day 9 onwards. Treatment with an aqueous extract from the rhizome of Gastrodia elata (GE) improves locomotion from days 12-23.

(Ng et al., 2013)

Flies expressing Scer\GAL4^GMR.PF>Hsap\APP^{Aβ42.Scer\UAS} show mild and severe eye degeneration phenotypes when cultured in normal food. The severity of eye degeneration is enhanced in Cu treated flies as compared with untreated flies, while the percentage of flies showing severe defect is unaltered. Treatment of flies with compound L (2,6-Pyridinedicarboxylic acid, 2,6-bis(2-((4-carboxyphenyl) methylene) hydrazide)) ameliorates the eye neurodegeneration phenotypes.

(Singh et al., 2013)

Expression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PLu results in vacuolisation in both the cortex and neuropil region of 20 day old flies.

Flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PLu begin to display locomotor defects at between 20 and 25 days old. Lifespan is also shortened compared to controls. When mutant flies are subjected to olfactory aversive conditioning they exhibit memory defects from 5 days old.

(Lang et al., 2012)

No memory loss is detectable in 5-day-old adult flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU but 10-day-old flies display significant loss of memory in the aversive olfactory memory assay.

(Wang et al., 2012)

Brain neurons from both young (1 day old) and older (16 day old) flies expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} under the control of Scer\GAL4^Gad1.PU exhibit numerous large autophagy-lysosomal vesicles, and the older flies occasionally show necrotic-like intraneuronal degeneration and show significant neuron loss, as compared to controls.

Expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} under the control of Scer\GAL4^{elav.Switch.PO} during either larval stage only, the entire adult stage only, the first 15 days of adulthood or during days 21-36 (temporally controlled via RU486 feeding) leads to a significant decrease in maximum lifespan, as compared to non-RU486-treated controls.

(Ling and Salvaterra, 2011)

Evoked excitatory junction current in muscle 12 synapses in larval body-wall segments 4 an 5 are reduced upon presynaptic expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK}, under the control of Scer\GAL4^elav-C155. This finding is true at a range of Ca[2+] concentrations.

Post-synaptic expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK}, under the control of Scer\GAL4^G7, significantly increases the excitatory junction current across larval muscle synapses.

Expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} in both neuron and muscle cells, under the control of Scer\GAL4^arm.PS reduces EJC amplitude.

The frequency of mEJCs is significantly decreased upon neuronal expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} under the control of Scer\GAL4^elav-C155. Both frequency and amplitude are unaffected by muscle expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} (under the control of Scer\GAL4^G7).

The evoked release of synaptic vesicles is reduced in larvae with neuronal expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK}, under the control of Scer\GAL4^elav-C155 and increased upon expression in the muscle, under the control of Scer\GAL4^G7.

Long-term depression in EJCs at the neuromuscular junction is significantly enhanced by postsynaptic expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK}, under the control of Scer\GAL4^G7 or Scer\GAL4^C57.

Long-term depression in EJCs at the neuromuscular junction is not affected by neuronal expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK}, under the control of Scer\GAL4^elav-C155.

Oligomerization inhibitor 1,2-naphthoquinone reverses the reduced EJCs seen upon expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK}, under the control of Scer\GAL4^elav-C155, but has no effect on synaptic transmission enhancement due to muscle expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK}. Conversely, fibrillization inhibitor, apigenin, neutralises the enhanced EJCs caused by expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} in muscle but does not reverse the synaptic transmission depressed by neuronal expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK}. Furthermore, apigenin completely suppresses enhanced EJC long-term depression in larvae expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} in the muscle, under the control of Scer\GAL4^G7, while 1,2-naphthoquinone has no effect.

(Chiang et al., 2009)

Expression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa} in neurons driven by Scer\GAL4^elav-C155 induces mitochondrial mislocalisation. There are more mitochondria in the cell bodies of neurons, while there appears to be fewer of them in axons and dendrites. A similar phenotype is observed using Scer\GAL4^Cha.7.4 as a driver.

Flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} in neurons driven by Scer\GAL4^elav-C155 display age-dependent progressive locomotor dysfunction starting from 14 days after eclosion.

Flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} in cholinergic neurons driven by Scer\GAL4^Cha.7.4 display age-dependent progressive locomotor dysfunction by 17 days after eclosion.

(Iijima-Ando et al., 2009)

Expression of Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^ChAT.7.4 results in a significant reduction in lifespan, and progressive climbing defects, as compared to controls. Many neurons in these flies exhibit increased size, an increased volume of cytoplasm, subcellular damage to plasma membranes, nuclear membranes, organelles such as mitochondria, or small trafficking vesicles, correlated with the progressive accumulation of large autophagic vesicles at a post-lysosomal fusion stage. Neuropil areas also exhibit some damage as compared to controls.

(Ling et al., 2009)

Expression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa} driven by Scer\GAL4^elav-C155 results in neurodegeneration, locomotor dysfunction and decreased adult lifespan. 1 hour memory of 5 day old mutant flies is indistinguishable from controls, however, memory defects do manifest in 10 day old flies.

Scer\GAL4^elav-C155- or Scer\GAL4^ey-OK107-driven expression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa} results in neuropil degeneration in flies 79 days after eclosion.

Calyxes in the adult mushroom body expressing Scer\GAL4^ey-OK107-driven Hsap\APP^{Aβ1-42.Scer\UAS.cIa} start to degenerate 79 days after eclosion.

(Iijima et al., 2008)

Expression of Hsap\APP^{Aβ42.Scer\UAS} in the eye under the control of Scer\GAL4^GMR.PF results in a rough-eye phenotype.

(Fulga et al., 2007)

Expression of Hsap\APP^{Aβ42.Scer\UAS} using Scer\GAL4^elav-C155 reduces life span. Only approximately 50% of these flies are alive at 20 days, compared to approximately 95% of controls. By 28 days, all Hsap\APP^{Aβ42.Scer\UAS}, Scer\GAL4^elav-C155 flies are dead whereas 70-90% of control flies are still alive.

Starting around days 7-9, Hsap\APP^{Aβ42.Scer\UAS}, Scer\GAL4^elav-C155 flies show slower locomotion and altered tapping reflex and grooming routines.

(Finelli et al., 2004)

2- to 3-day old adults expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} under the control of Scer\GAL4^elav-C155 do not show any significant defects in a Pavlovian olfactory learning assay. The flies being to show a subtle, but statistically significant, learning defect at 6-7 days old, and the decline is most obvious in 14-15 day old flies. Defects are greater in male flies than in female flies (consistent with higher expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} in the male flies). Odour avoidance (to methylcyclohexanol) and electric shock reactivity is normal in 14- to 15-day old flies expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} under the control of Scer\GAL4^elav-C155. Adults expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} under the control of Scer\GAL4^elav-C155 start to show locomotor dysfunction after 3 weeks of age; the climbing ability of these flies in response to light tapping begins to decline significantly 20 days after eclosion and older flies stay at the bottom of the vial and cannot climb up the wall. The lifespan of flies expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} under the control of Scer\GAL4^elav-C155 is much shorter than that of control flies. Aged adults expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} under the control of Scer\GAL4^elav-C155 show extensive neurodegeneration; 45 day old flies have severe neuronal loss, as seen by the number of vacuoles in the Kenyon cell layer. The majority of dying neurons in the Kenyon cell layer show typical features of necrotic cell death; digested cytoplasm with swollen mitochondria, whereas nuclei are relatively intact. 3- and 14-day old adults do not show detectable abnormalities in the brain, but a small amount of cell loss starts to be apparent in 30-day old flies. Expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK} under the control of Scer\GAL4^OK107 also results in neurodegeneration.

(Iijima et al., 2004)

External Data

Linkouts

Interactions

Show genetic interaction network for Enhancers & Suppressors

Phenotypic Class

Enhanced by

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by Vha68-1^HMS02962, Scer\GAL4^elav-C155

(Wang et al., 2021)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal neuroanatomy | adult stage phenotype, enhanceable by Vha68-1^HMS02962, Scer\GAL4^elav-C155

(Wang et al., 2021)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by Vha68-1^HMS02581, Scer\GAL4^elav-C155

(Wang et al., 2021)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by Vha68-1[+]/Vha68-1¹

(Wang et al., 2021)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by Hpd^MI12465/Hpd[+]

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by Hpd^KK105686, Scer\GAL4^elav-C155

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by +/Df(3L)BSC839

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by +/Df(3L)BSC368

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by Df(3L)BSC797/+

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by Df(3L)BSC800/+

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by Df(3R)FDD-0317950/+

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, enhanceable by CG17249[+]/CG17249^A362

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal locomotor behavior | adult stage phenotype, enhanceable by sra^EY07182, Scer\GAL4^elav.PU

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has increased cell death | third instar larval stage phenotype, enhanceable by sra^EY07182, Scer\GAL4^elav.PU

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has partially lethal - majority live phenotype, enhanceable by CanA1^JF01871, Scer\GAL4^elav.PU

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, enhanceable by sra^EY07182, Scer\GAL4^elav.PU

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has partially lethal - majority live phenotype, enhanceable by sra^EY07182, Scer\GAL4^elav.PU

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has abnormal neuroanatomy | adult stage phenotype, enhanceable by Zip42C.1^UAS.cLa, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has abnormal locomotor behavior | adult stage phenotype, enhanceable by Zip42C.1^UAS.cLa, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has short lived phenotype, enhanceable by Zip42C.1^UAS.cLa, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal memory | adult stage | progressive phenotype, enhanceable by InR^UAS.cUa, Scer\GAL4^elav.PU

(Wang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal memory | adult stage | progressive phenotype, enhanceable by Egfr^UAS.cUa, Scer\GAL4^elav.PU

(Wang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior phenotype, enhanceable by Miro^Sd32/Miro[+]

(Iijima-Ando et al., 2009)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^ChAT.7.4 has abnormal locomotor behavior phenotype, enhanceable by rut¹

(Iijima-Ando et al., 2009)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior phenotype, enhanceable by Pka-R2^EP2162, Scer\GAL4^elav-C155

(Iijima-Ando et al., 2009)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior phenotype, enhanceable by Pka-R2^EY11550, Scer\GAL4^elav-C155

(Iijima-Ando et al., 2009)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior phenotype, enhanceable by Pka-C1^GD1276, Scer\GAL4^elav-C155

(Iijima-Ando et al., 2009)

NOT Enhanced by

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, non-enhanceable by AttA^{UAS.APEX2,Tag:HA}, Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has decreased efficacy of learning | adult stage phenotype, non-enhanceable by AttA^{UAS.APEX2,Tag:HA}, Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, non-enhanceable by DptA^{UAS.ORF.GW.Tag:HA}, Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has decreased efficacy of learning | adult stage phenotype, non-enhanceable by DptA^{UAS.ORF.GW.Tag:HA}, Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal neuroanatomy | adult stage phenotype, non-enhanceable by Hsap\TREM2^{13xlexAop.Tag:MYC,Tag:FLAG}/Hsap\TYROBP^{13xlexAop.Tag:MYC,Tag:FLAG}/Ecol\lexA^GAD.repo

(Sekiya et al., 2018)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal neuroanatomy | adult stage phenotype, non-enhanceable by Hpd^MI12465/Hpd[+]

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal size | adult stage phenotype, non-enhanceable by Hpd^MI12465/Hpd[+]

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal neuroanatomy | adult stage phenotype, non-enhanceable by Hpd^KK105686, Scer\GAL4^elav-C155

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal size | adult stage phenotype, non-enhanceable by Hpd^KK105686, Scer\GAL4^elav-C155

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal neuroanatomy | third instar larval stage phenotype, non-enhanceable by sra^EY07182, Scer\GAL4^elav.PU

(Lee et al., 2016)

Suppressed by

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, suppressible by Df(3R)Exel6202/+

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal sleep | adult stage phenotype, suppressible by fabp^hs.PG, Scer\GAL4^elav-C155

(Gerstner et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal sleep | adult stage phenotype, suppressible by Mmus\Fabp7^hs.PG, Scer\GAL4^elav-C155

(Gerstner et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^Tab2-201Y has abnormal neuroanatomy phenotype, suppressible by Shal^UAS.cPa, Scer\GAL4^Tab2-201Y

(Ping et al., 2015)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal neurophysiology phenotype, suppressible by Shal^UAS.cPa, Scer\GAL4^elav.PU

(Ping et al., 2015)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal learning phenotype, suppressible by Shal^UAS.cPa, Scer\GAL4^elav.PU

(Ping et al., 2015)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, suppressible by Shal^UAS.cPa, Scer\GAL4^elav.PU

(Ping et al., 2015)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, suppressible by Tspo^VDRC.cUa, Scer\GAL4^elav.PU

(Lin et al., 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal neuroanatomy phenotype, suppressible by Tspo^VDRC.cUa, Scer\GAL4^elav.PU

(Lin et al., 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has increased cell death phenotype, suppressible by Tspo^VDRC.cUa, Scer\GAL4^elav.PU

(Lin et al., 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, suppressible by Tspo^EY00814/CG2789[+]

(Lin et al., 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal neuroanatomy phenotype, suppressible by Tspo^EY00814/CG2789[+]

(Lin et al., 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has increased cell death phenotype, suppressible by Tspo^EY00814/CG2789[+]

(Lin et al., 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal locomotor behavior | adult stage phenotype, suppressible by Ctr1C^RNAi.UAS.cLa, Scer\GAL4^elav.PU

(Lang et al., 2013)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, suppressible by Ctr1C^RNAi.UAS.cLa, Scer\GAL4^elav.PU

(Lang et al., 2013)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal neuroanatomy | progressive phenotype, suppressible by Ctr1C^RNAi.UAS.cLa, Scer\GAL4^elav.PU

(Lang et al., 2013)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal locomotor behavior | adult stage phenotype, suppressible by Ctr1B^NIG.7459R, Scer\GAL4^elav.PU

(Lang et al., 2013)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, suppressible by Ctr1B^NIG.7459R, Scer\GAL4^elav.PU

(Lang et al., 2013)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal locomotor behavior | adult stage phenotype, suppressible by ATP7^EY07895, Scer\GAL4^elav.PU

(Lang et al., 2013)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, suppressible by ATP7^EY07895, Scer\GAL4^elav.PU

(Lang et al., 2013)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has abnormal neuroanatomy | adult stage phenotype, suppressible by Zip42C.1^RNAi.UAS, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has abnormal neuroanatomy | adult stage phenotype, suppressible by Zip42C.1^GD1830, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has abnormal locomotor behavior | adult stage phenotype, suppressible by Zip42C.1^RNAi.UAS, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has abnormal locomotor behavior | adult stage phenotype, suppressible by Zip42C.1^GD1830, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has short lived phenotype, suppressible by Zip42C.1^RNAi.UAS, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has abnormal memory | adult stage phenotype, suppressible | partially by Zip42C.1^UAS.cLa, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has abnormal memory | adult stage phenotype, suppressible | partially by Zip42C.1^RNAi.UAS, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior phenotype, suppressible by Pka-R2^GD15709, Scer\GAL4^elav-C155

(Iijima-Ando et al., 2009)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^ChAT.7.4 has abnormal locomotor behavior phenotype, suppressible by dnc¹

(Iijima-Ando et al., 2009)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)} has short lived phenotype, suppressible by Atg1[+]/Atg1^Δ3D

(Ling et al., 2009)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)} has short lived phenotype, suppressible by Atg5^RNAi.UAS/Scer\GAL4^ChAT.7.4

(Ling et al., 2009)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has short lived phenotype, suppressible by Nep2^EP3549, Scer\GAL4^elav-C155

(Finelli et al., 2004)

NOT suppressed by

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, non-suppressible by AttA^{UAS.APEX2,Tag:HA}, Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, non-suppressible by DptA^{UAS.ORF.GW.Tag:HA}, Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has decreased efficacy of learning | adult stage phenotype, non-suppressible by AttA^{UAS.APEX2,Tag:HA}, Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has decreased efficacy of learning | adult stage phenotype, non-suppressible by DptA^{UAS.ORF.GW.Tag:HA}, Scer\GAL4^elav.PU

(Hsieh and Chiang, 2023)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal neuroanatomy | adult stage phenotype, non-suppressible by Hsap\TREM2^{13xlexAop.Tag:MYC,Tag:FLAG}/Hsap\TYROBP^{13xlexAop.Tag:MYC,Tag:FLAG}/Ecol\lexA^GAD.repo

(Sekiya et al., 2018)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has abnormal locomotor behavior | adult stage | progressive phenotype, non-suppressible by +/Df(3R)ED6280

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Hsap\MAPT^UAS.cWa, Scer\GAL4^GMR.PF has visible phenotype, non-suppressible by sgg^GL00277, Scer\GAL4^GMR.PF

(Ando et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Hsap\MAPT^UAS.cWa, Scer\GAL4^GMR.PF has abnormal size | adult stage phenotype, non-suppressible by sgg^GL00277, Scer\GAL4^GMR.PF

(Ando et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^Tab2-201Y has abnormal neuroanatomy phenotype, non-suppressible by Sh^{EKO.UAS.GFP(GL)}, Scer\GAL4^Tab2-201Y

(Ping et al., 2015)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has short lived phenotype, non-suppressible by fz2^UAS.GFP, Scer\GAL4^elav.PU

(Lüchtenborg and Katanaev, 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^Toll-6-D42 has short lived phenotype, non-suppressible by fz2^UAS.GFP, Scer\GAL4^Toll-6-D42

(Lüchtenborg and Katanaev, 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PU has visible phenotype, non-suppressible by sgg^GD1331, Scer\GAL4^GMR.PU

(Lüchtenborg and Katanaev, 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PU has visible phenotype, non-suppressible by Gαo^GTP.UAS, Scer\GAL4^GMR.PU

(Lüchtenborg and Katanaev, 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has abnormal memory | adult stage phenotype, non-suppressible by Ctr1C^RNAi.UAS.cLa, Scer\GAL4^elav.PU

(Lang et al., 2013)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has short lived phenotype, non-suppressible by Ide^EP3099, Scer\GAL4^elav-C155

(Finelli et al., 2004)

Enhancer of

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PU is an enhancer of abnormal neuroanatomy | larval stage phenotype of Scer\GAL4^GMR.PU, sra^EY07182

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU is an enhancer of partially lethal - majority live phenotype of CanA1^JF01871, Scer\GAL4^elav.PU

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU is an enhancer of short lived phenotype of Scer\GAL4^elav.PU, sra^EY07182

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU is an enhancer of increased cell death | third instar larval stage phenotype of Scer\GAL4^elav.PU, sra^EY07182

(Lee et al., 2016)

Phenotype Manifest In

Enhanced by

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has adult brain phenotype, enhanceable by Vha68-1^HMS02962, Scer\GAL4^elav-C155

(Wang et al., 2021)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has embryonic/larval brain | third instar larval stage phenotype, enhanceable by sra^EY07182, Scer\GAL4^elav.PU

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has adult brain phenotype, enhanceable by Zip42C.1^UAS.cLa, Scer\GAL4^elav.PLu

(Lang et al., 2012)

NOT Enhanced by

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has adult brain phenotype, non-enhanceable by Hsap\TREM2^{13xlexAop.Tag:MYC,Tag:FLAG}/Hsap\TYROBP^{13xlexAop.Tag:MYC,Tag:FLAG}/Ecol\lexA^GAD.repo

(Sekiya et al., 2018)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has adult brain phenotype, non-enhanceable by Hpd^MI12465/Hpd[+]

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has adult brain phenotype, non-enhanceable by Hpd^KK105686, Scer\GAL4^elav-C155

(Belfiori-Carrasco et al., 2017)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has embryonic/larval glial cell | third instar larval stage | increased number phenotype, non-enhanceable by CanA1^JF01871, Scer\GAL4^elav.PU

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has embryonic/larval glial cell | third instar larval stage | increased number phenotype, non-enhanceable by sra^EY07182, Scer\GAL4^elav.PU

(Lee et al., 2016)

Suppressed by

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^Tab2-201Y has Kenyon cell phenotype, suppressible by Shal^UAS.cPa, Scer\GAL4^Tab2-201Y

(Ping et al., 2015)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU has adult brain phenotype, suppressible by Ctr1C^RNAi.UAS.cLa, Scer\GAL4^elav.PU

(Lang et al., 2013)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has adult brain phenotype, suppressible by Zip42C.1^RNAi.UAS, Scer\GAL4^elav.PLu

(Lang et al., 2012)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PLu has adult brain phenotype, suppressible by Zip42C.1^GD1830, Scer\GAL4^elav.PLu

(Lang et al., 2012)

NOT suppressed by

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav-C155 has adult brain phenotype, non-suppressible by Hsap\TREM2^{13xlexAop.Tag:MYC,Tag:FLAG}/Hsap\TYROBP^{13xlexAop.Tag:MYC,Tag:FLAG}/Ecol\lexA^GAD.repo

(Sekiya et al., 2018)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Hsap\MAPT^UAS.cWa, Scer\GAL4^GMR.PF has eye phenotype, non-suppressible by sgg^GL00277, Scer\GAL4^GMR.PF

(Ando et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^Tab2-201Y has Kenyon cell phenotype, non-suppressible by Sh^{EKO.UAS.GFP(GL)}, Scer\GAL4^Tab2-201Y

(Ping et al., 2015)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PU has eye phenotype, non-suppressible by sgg^GD1331, Scer\GAL4^GMR.PU

(Lüchtenborg and Katanaev, 2014)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PU has eye phenotype, non-suppressible by Gαo^GTP.UAS, Scer\GAL4^GMR.PU

(Lüchtenborg and Katanaev, 2014)

Enhancer of

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PU is an enhancer of eye disc | larval stage phenotype of Scer\GAL4^GMR.PU, sra^EY07182

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PU is an enhancer of photoreceptor neuron | larval stage phenotype of Scer\GAL4^GMR.PU, sra^EY07182

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PU is an enhancer of axon | third instar larval stage phenotype of Scer\GAL4^GMR.PU, sra^EY07182

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PU is an enhancer of embryonic/larval brain phenotype of Scer\GAL4^GMR.PU, sra^EY07182

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU is an enhancer of embryonic/larval brain | third instar larval stage phenotype of Scer\GAL4^elav.PU, sra^EY07182

(Lee et al., 2016)

NOT Enhancer of

Statement

Reference

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU is a non-enhancer of embryonic/larval glial cell | third instar larval stage | increased number phenotype of CanA1^JF01871, Scer\GAL4^elav.PU

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^elav.PU is a non-enhancer of embryonic/larval glial cell | third instar larval stage | increased number phenotype of Scer\GAL4^elav.PU, sra^EY07182

(Lee et al., 2016)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PF is a non-enhancer of eye phenotype of Hsap\MAPT^E14.UAS, Scer\GAL4^GMR.PF

(Fulga et al., 2007)

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}, Scer\GAL4^GMR.PF is a non-enhancer of eye phenotype of Hsap\MAPT^AP.UAS, Scer\GAL4^GMR.PF

(Fulga et al., 2007)

Additional Comments

Genetic Interactions

Statement

Reference

Xenogenetic Interactions

Statement

Reference

The decreased locomotion in 18 days old adults induced by the expression of Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)} under the control of Scer\GAL4^elav-C155 is enhanced either by the co-expression of Hpd^KK105686 or by heterozygosity for Df(3L)BSC839, Df(3L)BSC368, Df(3L)BSC797, Df(3L)BSC800, Df(3R)FDD-0317950, CG17249^A362 or Hpd^MI12465, is suppressed by heterozygosity for Df(3R)Exel6202, and is not affected by heterozygosity for Df(3R)ED6280; the observed adult brain loss and vacuolization, however, are not affected by the co-expression of Hpd^KK105686 or by heterozygosity for Hpd^MI12465.

(Belfiori-Carrasco et al., 2017)

The sleep loss and fragmentation induced by Scer\GAL4^elav-C155-driven expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} are rescued by co-expression of either fabp^hs.PG or Mmus\Fabp7^hs.PG.

(Gerstner et al., 2017)

The small eye size observed upon expression of Hsap\MAPT^Scer\UAS.cWa driven by Scer\GAL4^GMR.PF is enhanced by the co-expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} alone; this enhancement is not suppressed by also co-expressing sgg[GL00277].

Co-expression of Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} and Hsap\MAPT^{S2A.Scer\UAS.0N4R} under the control of Scer\GAL4^GMR.PF results in eye sizes comparable to controls.

Adults co-expressing Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK} and sgg^GL00277 under the control of Scer\GAL4^GMR.PF have eye sizes comparable to controls.

(Ando et al., 2016)

The increased mortality during development as well as the reduced climbing abilities of adults characteristic for flies expressing Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^elav.PU are aggravated further by co-expression of sra^EY07182.

The decreased adult life-span observed both in flies expressing sra^EY07182 or Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^elav.PU is reduced further when the two transgenes are co-expressed.

The high level of cell death in third instar larval brain as well as the reduced adult survival rate under oxidative stress conditions seen in flies expressing either Hsap\APP^{Aβ42.Scer\UAS} or sra^EY07182 under the control of Scer\GAL4^elav.PU are aggravated further when the two transgenes are expressed simultaneously.

The increased number of glial cells in third instar larval brain observed in larvae expressing either Hsap\APP^{Aβ42.Scer\UAS}, sra^EY07182 or CanA1^JF01871 under the control of Scer\GAL4^elav.PU does not increase further when either Hsap\APP^{Aβ42.Scer\UAS} and sra^EY07182 or Hsap\APP^{Aβ42.Scer\UAS} and CanA1^JF01871 are co-expressed.

The increased mortality during development characteristic for flies expressing either Hsap\APP^{Aβ42.Scer\UAS} or under the control of CanA1^JF01871 is dramatically increased if both Hsap\APP^{Aβ42.Scer\UAS} and CanA1^JF01871 are expressed simultaneously.

(Lee et al., 2016)

Expression of Shal^Scer\UAS.cPa suppresses the increased excitability seen in primary neurons that have been dissociated from late-gastrula stage embryos expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU. The average current required to induce action potential firing is similar to controls.

Expression of Shal^Scer\UAS.cPa suppresses the learning defects seen in larvae expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} pan-neuronally under the control of Scer\GAL4^elav.PU.

Expression of Shal^Scer\UAS.cPa suppresses the climbing defects and mushroom body neuron loss seen in flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU to near wild type levels.

Expression of Shal^Scer\UAS.cPa suppresses the mushroom body neuron loss seen in flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} specifically in the mushroom body under the control of Scer\GAL4^Tab2-201Y.

Expression of Shal^Scer\UAS.cPa slightly but significantly suppresses the reduction in lifespan seen when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PU.

Expression of Sh^Scer\UAS.cJa does not suppress the learning defects seen in larvae expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} pan-neuronally under the control of Scer\GAL4^elav.PU.

Expression of Sh^Scer\UAS.cJa does suppress the progressive climbing defects seen in adult flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} pan-neuronally under the control of Scer\GAL4^elav.PU.

Expression of Sh^Scer\UAS.cJa suppresses the mushroom body neuron cell loss seen in adult flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} pan-neuronally under the control of Scer\GAL4^elav.PU at 25 days, but not at 40 days.

Expression of Sh^Scer\UAS.cJa does not suppress the reduction in lifespan seen when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PU.

Expression of Sh^{EKO.Scer\UAS.T:Avic\GFP-GL} does not suppress the learning defects seen in larvae expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} pan-neuronally under the control of Scer\GAL4^elav.PU. The progressive climbing defects seen in adult flies are also not suppressed.

Expression of Sh^{EKO.Scer\UAS.T:Avic\GFP-GL} does not suppress the mushroom body neuron loss seen in flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} specifically in the mushroom body under the control of Scer\GAL4^Tab2-201Y.

Expression of Sh^{EKO.Scer\UAS.T:Avic\GFP-GL} does not suppress the reduction in lifespan seen when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PU.

(Ping et al., 2015)

Expression of fz2^{Scer\UAS.T:Avic\GFP} does not suppress the reduction in lifespan seen when Hsap\APP^{Aβ42.Scer\UAS} is expressed in motoneurons under the control of Scer\GAL4^D42.

Expression of fz2^{Scer\UAS.T:Avic\GFP} does not suppress the reduction in lifespan seen when Hsap\APP^{Aβ42.Scer\UAS} is expressed pan-neuronally under the control of Scer\GAL4^elav.PU.

Expression of sgg^GD1331 does not suppress the reduction in lifespan seen when Hsap\APP^{Aβ42.Scer\UAS} is expressed in motoneurons under the control of Scer\GAL4^D42.

Expression of sgg^GD1331 does not suppress the reduction in lifespan seen when Hsap\APP^{Aβ42.Scer\UAS} is expressed pan-neuronally under the control of Scer\GAL4^elav.PU.

Expression of sgg^GD1331 does not suppress the rough eye phenotype seen when Hsap\APP^{Aβ42.Scer\UAS} is expressed pan-neuronally under the control of Scer\GAL4^GMR.PU.

Expression of Gαo^GTP.Scer\UAS does not suppress the rough eye phenotype seen when Hsap\APP^{Aβ42.Scer\UAS} is expressed pan-neuronally under the control of Scer\GAL4^GMR.PU.

(Lüchtenborg and Katanaev, 2014)

Co-expression of Ctr1C^{dsRNA.Scer\UAS.cLa} partially suppresses the climbing defects and reduced lifespan of adults expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU. The double mutant flies show defects in climbing ability starting at 30 days of age and show a 32.4% increase in median lifespan compared to Hsap\APP^{Aβ1-42.Scer\UAS.cIa}, Scer\GAL4^elav.PU single mutant flies.

Co-expression of Ctr1C^{dsRNA.Scer\UAS.cLa} significantly decreases the neurodegeneration seen in the brains of 30 day old adults expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU.

Co-expression of Ctr1C^{dsRNA.Scer\UAS.cLa} does not rescue the impaired memory performance of 10 day old adults expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU in an olfactory aversive conditioning assay.

Co-expression of Ctr1C^{dsRNA.Scer\UAS.cLa} significantly increases the resistance of flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU to paraquat.

Co-expression of Ctr1B^NIG.7459R ameliorates the climbing defects and reduced lifespan of adults expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU.

Co-expression of ATP7^EY07895 ameliorates the climbing defects and reduced lifespan of adults expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU.

(Lang et al., 2013)

Expression of ZIP1^Scer\UAS.cLa enhances the brain vacuolisation phenotype seen in 20 day old flies when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu.

Expression of ZIP1^{dsRNA.Scer\UAS} suppresses the brain vacuolisation phenotype seen in 20 day old flies when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu.

Expression of ZIP1^GD1830 suppresses the brain vacuolisation phenotype seen in 20 day old flies when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu.

Expression of ZIP1^Scer\UAS.cLa enhances the locomotor defects seen when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu. Flies begin to display climbing defects at around 15 days after eclosion, as opposed to 20-25 days when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed alone.

Expression of ZIP1^{dsRNA.Scer\UAS} suppresses the locomotor defects seen when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu. Flies begin to display climbing defects at around 30 days after eclosion, as opposed to 20-25 days when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed alone.

Expression of ZIP1^GD1830 suppresses the locomotor defects seen when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu. Flies do not begin to display climbing defects until around 30 days after eclosion, rather than 20-25 days as is seen when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed alone.

Expression of ZIP1^Scer\UAS.cLa enhances the reduction in lifespan seen when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu. Median lifespan is reduced by 12.5% and 22.2% at 25[o]C and 29[o]C respectively.

Expression of ZIP1^{dsRNA.Scer\UAS} suppresses the reduced lifespan seen when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu. An increase in the median lifespan is seen at both 25[o]C and 29[o]C.

Expression of ZIP1^Scer\UAS.cLa partially suppresses the memory loss seen in 5 day old flies when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu.

Expression of ZIP1^{dsRNA.Scer\UAS} partially suppresses the memory loss seen in 5 day old flies when Hsap\APP^{Aβ1-42.Scer\UAS.cIa} is expressed under the control of Scer\GAL4^elav.PLu.

(Lang et al., 2012)

The age-progressive memory induced by expression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav.PU is enhanced by co-expression of either Egfr^Scer\UAS.cUa or InR^Scer\UAS.cUa : the memory defect are detectable even in young 5-day-old flies that perform normally in the aversive olfactory memory assay when expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} alone.

(Wang et al., 2012)

Miro^Sd32 heterozygosity enhances the locomotor defects in flies induced by Scer\GAL4^elav-C155-driven overexpression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa}.

Flies overexpressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} driven by Scer\GAL4^Cha.7.4 in a rut¹ mutant background display age-dependent progressive locomotor dysfunction significantly earlier than Hsap\APP^{Aβ1-42.Scer\UAS.cIa}-overexpressing flies without rut¹ in the genetic background.

dnc¹ suppresses the locomotor defects in flies induced by Scer\GAL4^Cha.7.4-driven overexpression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa}.

Co-expression of Pka-C1^GD1276 enhances the locomotor defects in flies induced by Scer\GAL4^elav-C155-driven overexpression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa}.

Co-expression of Pka-R2^EP2162 enhances the locomotor defects in flies induced by Scer\GAL4^elav-C155-driven overexpression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa}.

Co-expression of Pka-R2^EY11550 enhances the locomotor defects in flies induced by Scer\GAL4^elav-C155-driven overexpression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa}.

Co-expression of Pka-R2^GD15709 suppresses the locomotor defects in flies induced by Scer\GAL4^elav-C155-driven overexpression of Hsap\APP^{Aβ1-42.Scer\UAS.cIa}.

(Iijima-Ando et al., 2009)

Atg1^Δ3D/+ leads to partial suppression of the lifespan reduction seen in flies expressing Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^ChAT.7.4.

Co-expression of Atg5^{dsRNA.Scer\UAS} leads to partial suppression of the lifespan reduction seen in flies expressing Hsap\APP^{Aβ42.Scer\UAS} under the control of Scer\GAL4^ChAT.7.4.

(Ling et al., 2009)

Expression of Hsap\MME^Scer\UAS.cIa dramatically suppresses the neuron loss seen in the brains of 28 day old flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav-C155. Fewer vacuoles are seen in the cell body regions. The reduction in lifespan is not rescued.

Expression of Hsap\MME^mut.Scer\UAS does not suppress the neuron loss seen in the brains of 28 day old flies expressing Hsap\APP^{Aβ1-42.Scer\UAS.cIa} under the control of Scer\GAL4^elav-C155. The reduction in lifespan is not rescued.

(Iijima-Ando et al., 2008)

Expression of Hsap\APP^{Aβ42.Scer\UAS} and Hsap\MAPT^Scer\UAS.cWa in the eye under the control of Scer\GAL4^GMR.PF results in a severe rough-eye phenotype, enhanced compared to over-expression of each transgene alone.

Expression of Hsap\APP^{Aβ42.Scer\UAS} in flies expressing Hsap\MAPT^E14.Scer\UAS under the control of Scer\GAL4^GMR.PF does not enhance the rough-eye phenotype.

Expression of Hsap\APP^{Aβ42.Scer\UAS} in flies expressing Hsap\MAPT^AP.Scer\UAS under the control of Scer\GAL4^GMR.PF does not enhance the rough-eye phenotype.

(Fulga et al., 2007)

Co-expression of Nep2^EP3549, but not Ide^EP3099, suppresses the reduced life span seen in Hsap\APP^{Aβ42.Scer\UAS}, Scer\GAL4^elav-C155 flies.

(Finelli et al., 2004)

Complementation and Rescue Data

Comments

Images (0)

Mutant

Wild-type

Stocks (0)

Notes on Origin

Discoverer

External Crossreferences and Linkouts ( 0 )

Synonyms and Secondary IDs (5)

Reported As

Symbol Synonym

Hsap\APP^{Aβ1-42.Scer\UAS.cIa}

Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\PENK}

Hsap\APP^{Aβ42.Scer\UAS.T:Rnor\SS-PENK}

Hsap\APP^{Aβ42.Scer\UAS}

Hsap\APP^{Aβ42.UAS.Tag:SS(rPENK)}

Name Synonyms

Secondary FlyBase IDs

FBal0183231
FBal0246258
FBal0243228

References (50)

Report Sections

Open Close